Hims & Hers Health (HIMS) Stock: Buy, Sell, or Hold?
HIMS - Hims & Hers Health, Inc.
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 4, 2026 at $27.71 · last confirmed Sep 11, 2026
Get Alerted When HIMS Hits Your Target Price
Join 10,000+ traders who never miss a move
Interactive Price Chart (1 Month)
Loading historical data...
📊 MIXED SIGNALS: HIMS shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Technical Outlook: Technically, HIMS is in a downtrend. The price is currently testing key support at $26.73. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: HIMS scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $31.23 (+13.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Protect Your Profits
Holding HIMS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (37/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($31.23)
- BULLISH: Expecting earnings turnaround to 11.4% growth with 38.2% revenue growth
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
Support & Resistance Levels
Fundamental Context
Data refreshes hourly during market hours. Next update: 11:50 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Is HIMS showing a specific setup today?
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary Sh… |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
Advanced HIMS Option Strategies
Professional options setups generated by AI based on today's HIMS price and gamma walls.
